BATH, England, October 3, 2017 /PRNewswire/ --
Expanded Board and Blue
Chip Investors Position Company for Global
Reach
Atlas Genetics Ltd., the ultra-rapid, point-of-care (POC)
testing company for women's and family health, today announced that
Jeffrey R. Luber has been appointed
Chief Executive Officer effective 1 October
2017. Dr John Clarkson,
current founding CEO, will become Executive Chairman and current
chairman, Neil Butler, will remain
with the Company as a non-executive director of the Board.
Mr. Luber joins the Board of Atlas Genetics with broad
experience in the life sciences industry, including having held
multiple leadership roles in both public and private companies.
Most recently, he led the return to growth and sale of Good Start
Genetics to Invitae Corp (NYSE: NVTA). In this role, Jeff led the
company in new directions, restoring growth to its core business,
expanding its reach into consumer markets, and entering into
transformative strategic partnerships with Roche Diagnostics and
Amazon. Prior to this, Jeff was CEO of EXACT Sciences (NASDAQ:
EXAS) where he executed its successful turnaround and strategic
transaction with Genzyme Corp.
Dr John Clarkson, founding CEO
of Atlas Genetics, said:
"We are delighted to welcome Jeff to
Atlas Genetics. Jeff's proven
track record and extensive experience in the
commercialisation of in vitro diagnostics will be invaluable
as we enter the next, exciting phase of growth aimed
at improving the diagnosis and treatment of
conditions affecting women and
families."
Mr Jeffrey Luber,
commented:
"I am thrilled to join
Atlas Genetics, given the power of its platform,
the strength of its board and leadership team,
and its experienced investor syndicate.
Dr. Clarkson has built
a world class team of scientists and engineers who
have developed a truly differentiating
technology platform in Point of Care testing
for broad global markets. As
diagnostic testing increasingly becomes more
decentralized, I look forward to working with the
team to make Atlas the
leading global player in
POC testing."
Florent Gros, Managing
Director of Novartis Venture Fund and
non-executive director of Atlas Genetics,
added:
"At Novartis Venture Fund, we seek out novel platforms
to address global unmet needs and stellar management to drive
innovation and growth. With Point of Care testing
expected to grow to 35% by 2020, from less than 1% today, we
are thrilled to have Jeff on board and look
forward to his leadership through this very
exciting next phase of global growth for the
company."
Atlas Genetics' Investors include Novartis Venture Fund, Johnson
& Johnson Innovation - JJDC, Inc., Consort Medical plc and
China-based Wondfo Biotech.
About Atlas Genetics
Atlas Genetics is an in vitro diagnostics company focused on
decentralized, near-patient and point-of-care (POC) testing for the
benefit of women and families globally. The Company's proprietary
technology platform is positioned to improve patient outcomes by
arming healthcare professionals with a simple-to-use, rapid and
cost-effective solution for on-demand diagnosis of infectious
diseases. Rapid turnaround times, high accuracy and low cost are
hallmarks of the company's broad platform for a broad range of
infectious diseases. The io® platform offers a
sample-to-answer time of 30 minutes, or less, making it possible to
carry out infectious disease tests in primary care clinics and
physicians' offices anywhere.
For further information visit www.atlasgenetics.com
Contact details:
Atlas Genetics Ltd:
Tel: +44 (0) 1225 717930
Jeff Luber & John Clarkson
jeff.luber@atlasgenetics.com
FTI Consulting:
Tel: +44 (0) 20 3727 1000
Mo Noonan/ Anna Foster
SOURCE Atlas Genetics